Haemophogocyticlymphohistiocytosis (HLH) is a rare but potentially fatal disease, which describes a clinical syndrome of hyper-inflammation resulting in uncontrolled and ineffective immune response. It appears commonly in infancy, although it has been seen in all age groups. A vast majority of cases are acquired due to secondary causes (infections, autoimmune, malignancy, metabolic disorders) but primary HLH (genetic) is also not uncommon which also gets triggered by infection as suggested by recent studies. "Hypercytokinemia" which is the hallmark of HLH can result in end organ damage and even death in some cases if there is delay in diagnosis. The pathological hallmark of this syndrome is uncontrolled activation of T lymphocytes and macrophages, together with an impaired cytotoxic function of NK cells and CD8+T lymphocytes resulting into massive cytokine release (e.g. interferon-ã, TNF-á, 8, 10, 12, 18) from this cells and overwhelming inflammation. Lymphocytes and macrophages sometimes with haemophagocytic activity accumulate in bone marrow, spleen, liver or lymph nodes. This disorder is characterized by fever, hepatosplenomegaly, lymphadenopathy, skin rash, cytopenias, hepatitis, coagulopathy, and neurological symptoms. We report a case of 55 yr. old male presenting with fever and high colored urine who developed clinical and laboratory findings consistent with diagnosis of HLH according to HLH-2004 guidelines. Unfortunately the patient died despite receiving chemotherapy. HLH has multifaceted clinical presentations with often non-specific signs and symptoms that are often found in other clinical conditions. Early recognition of HLH is critical in initiating therapy early and preventing high mortality resulting from multi-organ failure.
Introduction:
Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. 1 HLH presents as a febrile illness associated with multiple organ involvement. It may be primary or secondary HLH. 2 Primary HLH is better defined as "genetic" encompassing both the familial hemophagocytic lymphohistiocytosis (FHLH) and also HLH occurring in association with Chediak-Higashi syndrome, Griscelli syndrome type 2 and X-linked lymphoproliferative disorder. FHLH is inherited as an autosomal recessive manner and the incidence is higher in areas where parental consanguinity is common. 3 About 70% of the cases present before one year of age but only 10% are symptomatic in the neonatal period. Secondary HLH can present at any age. It has more variability in severity and outcome, although the clinical picture may be identical to primary HLH. It is seen in the context of infection, underlying autoimmune disorders (where it is often termed Macrophage Activation Syndrome; MAS), some metabolic disorders and malignancy (particularly T-cell lymphomas). 2 HLH is reported to occur with a wide variety of infections, including bacterial, viral, protozoal and fungal infections. 4 Many clinical episodes of primary HLH are also triggered by an acute infection. Herpes viruses, in particular EBV, are amongst the most common infections associated with HLH in children and young adults. 4 HLH may often mimic infectious illnesses, such as overwhelming bacterialsepsis and leptospirosis 5 and may also obscure the diagnosis of a precipitating, treatable infectious illness (as reported for visceral leishmaniasis). 6 HLH is also seen in association with a number of rheumatic diseases like SLE, systemic onset JIA and Kawasaki disease. 7 Clinical features are often similar to those in primaryHLH but the preceding high levels of inflammatory markers associated with the underlying diagnosis may blur laboratory findings. The presentation of HLH could be acute or insidious. In order to improve the diagnosis of HLH, the Histiocyte Society published diagnostic guidelines. Fever, hepatosplenomegaly and cytopenias are the cardinal features that should raise a doubt of this condition in the physicians mind. In addition to this, continued deterioration in spite of maximal care will almost confirm the diagnosis. We report a case of HLH in adult in order to illustrate the spectrum of clinical features and to emphasis the importance of prompt diagnosis and initiation of therapy.
Case Report:
Mr Montaz, 55-year-old, Muslim, male, BMI-20 kg/m 2 , cultivator, not known diabetic and hypertensive hailing from Rajbari had got admitted into Medicine department of Shaheed Suhrawardy Medical College Hospital on 3 rd July, 2017 with the complaints of high grade remittent fever for one and half months, highest recorded temperature was 105 o F and high coloururine for same duration which was orange to red in colour amounting to 1.5 to 2 Liters per day associated with occasional dysuria for same duration. He also complained of oral white curd like multiple spots involving inner chick and tongue including dysphagia for the last 1 month. He also gave history of significant weight loss (about 15 kg) during the period of his illness. He had H/O repeated exposure to insecticide during farming. He also gave history of occasional extramarital sexual exposure. He had no history of skin rash, headache, convulsion, vomiting, diarrhoea, cough, sore throat, hematemesis, melaena, no stigmata of chronic liver disease, no bleeding manifestation and no significant travel history. During in-hospital course of illness, the patient received empirically injectable broad-spectrum antibiotics (including meropenem) along with multiple PRBCs. Despite of supportive treatment the patient continued to remain febrile and there was progressive deterioration of general condition. At this stage with precaution and supportive care, bone marrow aspiration was done which revealed as hyper cellularity, M/E ratio decreased with hyperactive erythropoiesis with micronormoblastic and megaloid changes, granulopoiesis relatively depressed and maturing into segmented form. Megakaryocytes were normal. Lymphocytes and plasma cells were normal and also showed significant numbers of haemophagocytes altogether suggestive of Haemophagocytic-lymphohistocytosis (HLH), Fig: 1 . 
Discussion:
HLH encompasses a heterogeneous class of rare but potentially fatal disorders characterized by multi-system inflammation, that occurs due to prolonged and intense activation of antigen-presenting cells (macrophages, histiocytes) and CD8+T-cells, and excessive proliferation and ectopic migration of T-cells 8 resulting into consumption and apoptosis of various hematologic cell lines. The primary form (FHLH) is an inflammatory disease, which is similar to secondary one on the basis of symptoms. Age of onset of this variety is less than one year of age in 70% of cases but it can rarely be observed in the first two weeks of life. 4 In rare cases, it may occur in adults as well. Although several types of gene mutations e.g.; PRF 1, UNC 13D, STX 11,RAB27A, STXBP2, SH2D1A, XIAP, LYST etc. have been identified in patients with primary HLH 1,9 they all lead to the common phenotype of impaired cytotoxic function by NK and T cells, and a predisposition to develop HLH. Acquired (secondary) forms of HLH may develop as a result of strong immunological activation of the immune system, which may be caused by severe infections, rheumatologic disorders and malignancies. It generally occurs among older children and adults who present without a family history or known genetic cause. Leading triggering agents of infection-associated haemophagocytic syndrome (IAHS) are viruses of the herpes group, especially EBV 10 and CMV. 11 The patients in the original report by Risdallet al. were mostly associated with viral infection following organ transplantation. 12 Subsequently its association was established with many viruses as well as a number of bacteria, fungi, mycobacteria and parasite and the term Viral Associated Haemophagocytic Syndrome (VAHS) was redesigned as Infection Associated Haemophagocytic Syndrome (IAHS). A review of published cases in children with IAHS reported that more than half of them were from Far East and Epstein Barr Virus (EBV) was the triggering virus in 74% of the children 4 .
Fardetet al reported Human Herpes virus 8 associated HLH among HIV-infected patients. 13 Malignancy associated acquired HLH (MAHS), with lymphoma being the commonest trigger, is well known entity in adults but rare in children. In a recent review of patients with lymphoma associated haemophagocytic syndrome (LAHS) in Japan showed that EBV genome was detected from more than 80% of T/NK cell lymphoma but rarely from B cell lymphoma. 14 Macrophage activation syndrome (MAS) is a special form of HLH which occurs both in children and adults with autoimmune diseases, 15 and most commonly seen in association with systemic onset juvenile rheumatoid arthritis (sJRA) or adult onset Still's disease and rarely found with systemic lupus erythematosus or other entities. Clinical picture and laboratory findings are similar to HLH. Patients of sJRA were found to have low NK cell function and perforin expression compared to other form of rheumatoid arthritis. MAS are a grave disorder with a mortality of about 10-20%. It has been suggested by some rheumatologists that MAS be classified as a form of secondary HLH.
Categorizing patients as having either "primary" or "secondary" HLH at diagnosis is of limited value. Without a known genetic defect or family history, it is often not possible to make an initial diagnosis of "primary" or "secondary" HLH. Furthermore, a careful search for underlying disease triggers should be performed in all patients. However, recurrence of HLH, in the absence of autoimmune disease or malignancy, is generally considered to be good evidence that a patient has primary HLH. Despite attempts to differentiate primary from secondary HLH, the clinical presentation is highly overlapping, hence initial treatment should not be delayed or altered based on these categories. The clinical picture of HLH is nonspecific and differentiation of HLH from sepsis with disseminated intra vascular coagulation (DIC) can be difficult. Generally, the onset of HLH is acute or sub-acute, with persistent high-grade fever, anorexia, and weight loss. Enlargement of the spleen and liver are often seen in HLH. Rash, jaundice, edema, lymphadenopathy, and cerebromeningeal symptoms (meningitis, seizures, gait and balance problems, etc.) 16 can also be present. Life threatening multi organ failure is frequently seen in fullpictured HLH. The fever often fluctuates with complete remission and recurrence. Patients may have a variety of skin manifestations, including generalized maculopapular erythematous rashes, generalized erythroderma, edema, panniculitis, morbilliform erythema, petechiae, and purpura. 17 The incidence of skin manifestations ranges from 6%-65% with highly pleomorphic presentations. Some patients may present with features suggestive of Kawasaki disease, including erythematous rashes, conjunctivitis, red lips, and enlarged cervical lymph nodes. 18 Patients may develop pulmonary dysfunction, which is an ominous sign. Our patient developed acute respiratory failure and needed ICU support including mechanical ventilation. More than one-third of patients will present with neurologic symptoms, including seizures, meningism, altered level of consciousness, cranial nerve palsy, psychomotor retardation, ataxia, irritability, or hypotonia. 16 Patient may have even only neurological manifestations. The cerebrospinal fluid (CSF) is abnormal in >50% of HLH patients with findings of pleocytosis, elevated protein, and/or haemophagocytosis. MRI findings are variable, including discrete lesions, leptomeningeal enhancement, or global edema, and images correlate with neurologic symptoms. 19 Retinal hemorrhages, swelling of the optic disc and infiltration of the choroid have been reported in infants with HLH. 20 Diffuse peripheral neuropathy with pain and weakness secondary to myelin destruction by macrophages may also occur. The workup for HLH includes a complete and differential blood count, renal function tests, liver function tests, fasting triglycerides, international normalized ratio, partial thromboplastin time, fibrinogen, and ferritin. The most characteristic laboratory findings in HLH are cytopenia affecting at least 2 cell lineages in peripheral blood and hyperferritinemia, often "sky high">10,000 g/L. 21 Anemia and thrombocytopenia occur in > 80% of patients at the time of presentation 21 , that depends on combination of haemophagocytosis, hypersplenism and massive cytokine release by activated macrophages (e.g, INF-, TNF-). 22 Thrombocytopenia is almost always present and can lead to severe bleeding, especially in the presence of coagulopathy (e.g. low fibrinogen level). Hepatic manifestations of HLH include a moderate increase in serum transaminases, pronounced cholestasis, raised serum bilirubin, decreased serum albumin and coagulation factors deficiency. 23 Most patients have variable evidence of hepatitis at presentation. Autopsy evaluation study of the liver has shown chronic persistent hepatitis with periportal lymphocytic infiltration in 22 of 27 patients with HLH. 24 Hypertriglyceridemia, hypofibrinogenemia, elevated serum lactate dehydrogenase, hyponatremia are frequently seen in HLH. Elevated VLDL and decreased HDL may also be present. 24 Nearly 95% of patients have features of disseminated intravascular coagulation and are at high risk for acute bleeding 25 & associated with high (>70%) mortality when present. Elevated ferritin levels (>10,000 ìg/L) are reported to be 90% sensitive and 96 % specific for HLH in children. 26 although this has not been validated in adults.
Investigations for secondary triggers of HLH include investigations for viral infections (particularly EBV, HSV, HIV and CMV) and for malignancies as clinically indicated. A search for these etiologic agents was performed in our patient. However it should be emphasized that with the possible exception of leishmaniasis, anti-infectious therapy alone is not sufficient to control HLH. A lumbar puncture is also recommended as part of a diagnostic workup, and more than half of patients will have a moderate pleocytosis and/or increased protein content, even in the absence of neurological symptoms. The caution with lumbar puncture must be taken with regard to apossibly increased intracranial pressure.
All patients should have a bone marrow aspiration. However, frank haemophagocytosis may not be observed early in the course of the disease, and serial marrow aspirates may be helpful. Haemophagocytosis might be found in the first bone marrow aspiration of a FHLH patient but the absence of it will not rule out this diagnosis. As a result, if the bone marrow is not conclusive, material should be obtained from other organs e.g.; liver, spleen, and lymph nodes and occasionally the central nervous system, skin and serial aspirates over time may also be helpful. In our case, the bone marrow aspiration was performed and it revealed haemophagocytosis. Activated macrophages may engulf erythrocytes, leukocytes, and platelets, their precursors, and cellular fragments. Although haemophagocytosis in bone marrow is associated with HLH, the morphologic phenomenon may also be induced by more common events, including blood transfusions, infection, autoimmune disease, and other forms of bone marrow failure or causes of red blood cell destruction. Despite the nomenclature of HLH, diagnosis should never be made or excluded solely on the presence or absence of haemophagocytosis. Infiltration of bone marrow or liver by activated macrophages, along with global clinical evaluation, may distinguish HLH from other causes of haemophagocytosis.Two highly sensitive diagnostic parameters are low natural killer (NK) cell activity 27, 28, 29 and a hypercytokinemia, in particular elevated alpha chain of the soluble interleukin-2 receptor (sIL-2r, sCD25) in serum 30, 31 and in the CSF. 31, 32 NK cell activity helps to differentiate between reactive forms of HLH from familial type. In patients with FHLH, NK cell number is normal, but the activity is persistently decreased or absent. Patients with acquired HLH may have low NK cell number; NK cell function is decreased with active disease, but usually reverts to normal after treatment. 21 The laboratory workup should involve perforin expression by NK cell by using flow cytometry. Patients lacking perforin expression should be analyzed for the PRFI gene mutation. Molecular studies for HLH include mutations in perforin (PRF), Munc (UNC13D), syntaxin 11(STX11) and others can be done at specialized centers.
To assist with the rapid diagnosis of HLH, the Histiocyte Society has developed a set of diagnostic guidelines that encompass both clinical which are summarized in Table-1. 33   Table 1 Molecular diagnosis compatible with hemophagocyticlymphohistiocytosis 33 At least five out of the eight following criteria are needed for diagnosis of HLH. In the absence of a family history or specific molecular diagnosis, an assemblage of at least five of the eight diagnostic criteria are needed for a diagnosis of HLH and initiation of therapy. 33 At the end after ruling out other diagnoses and considering the fact that our patient had five criteria for HLH (fever, splenomegaly, hyperferritinemia, hypertriglyceridaemia and haemophagocytosis in bone marrow), we decided that HLH is the most probable diagnosis. It is important to consider the fact that none of these eight criteria are specific for HLH diagnosis and might be found in sepsis, SIRS and MODS. 34, 35, 36 For example the etiology of hypertriglyceridemia in these states can be multifactorial such as insulin resistance 37, 38 and inhibition of lipoprotein lipase activity 39, 40 . High level of serum ferritin has also been associated with inflammatory states and is frequently seen in toxic patients due to the up regulation of hemoxygenase-1 (heat shock protein). 41, 42 Ferritin is also an anti-apoptotic agent in ischemia-reperfusion injury 43 . Elevated soluble IL-2 receptor (CD25) is also observed in sepsis, SIRS and can be a predictive marker in neonatal sepsis. 44, 45 Similar to HLH disease, NK-cell activity is also decreased in sepsis and thermal injury. 46 The therapy of any form of HLH should focus on: (1) suppression of the life-threatening hyper-inflammatory status by destruction of activated CD8+T lymphocytes and macrophages, and (2) treatment of any existing HLH triggers. 22, 33, 47 In cases of FHL, an additional aim is correction of the underlying immune defect. 22, 33, 48 The first prospective international treatment protocol for HLH (HLH-94) was introduced in 1994. 49 The 22, 33 In summary, patients with sHLH could be started on therapy without etoposide, as long as treatment adjustments are made rapidly in refractory cases. 64 Initial treatment is given for eight weeks, and patients with persistent disease or an underlying genetic abnormality (primary HLH) should go on to continuation therapy as a bridge to allogeneic stem cell transplantation. In patients with poor performance status and multi-organ dysfunction, palliation is reasonable.
Although symptoms and laboratory features improve within 2 to 3 weeks, in some cases cytopenia may persist. In these cases bone marrow examination should be repeated to differentiate between non-response and myelosuppression due to etoposide. If there is no response, then unlikely to have benefit with medical treatment. There is no established salvage regimen. Isolated patient has responded to daclizumab, alemtuzumab or to stem cell transplantation. Hasegawa et al reported remission of HLH after syngeneic bone marrow transplantation. 65 Despite treatment, the prognosis of both familial and acquired forms of HLH is usually poor and is rapidly fatal in untreated cases. The CNS disease can cause relapses and may results into irreversible disability. Since HLH can be rapidly fatal without specific intervention, it is recommended that treatment be started when there is a high clinical suspicion, even when results of some diagnostic studies are still pending.
Conclusion:
HLH is a syndrome of uncontrolled immune activation that has become increasingly recognized over the past decade. It can be due to an underlying defect in cytotoxic function or secondary to a trigger, frequently in the setting of immunosuppression or a genetic predisposition. In adults, HLH is often associated with a malignant, infectious, or autoimmune disorder. Early recognition is crucial and without prompt treatment HLH is often fatal. Treatment includes targeting the underlying disorder and controlling the immune dysregulation. Etoposide, dexamethasone, and ultimately HSCT are the mainstay for the majority of patients with HLH. Despite treatment, the prognosis of both familial and acquired forms of HLH is usually poor and is rapidly fatal in untreated cases. Further studies are required to improve our understanding of the optimal treatment of HLH in adults.
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